 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
Kidney Cancer
ABT 510
| Synthetic peptide |
Abbott |
II |
| ABT 751 |
Antimitotic sulfonamide |
Abbott |
II |
| ABX-EGF |
Anti-EGF monoclonal antibody |
Abgenix and Amgen |
II |
| Ampligen |
RNA |
Hemispherx Biopharma |
II |
| Atrasentan |
Endthelial receptor agonist |
Abbott Laboratories |
II |
| Avastin (bevacizumab) |
Anti-VEGF |
Genentech |
III |
| BAY 43-9006 (sorafenib) |
MKI VEGFR-2, VEGFR-3, PDGFR-B, RAF, Kit, FLT-3, RET |
Bayer Pharmaceuticals Onyx Pharmaceuticals |
Approved 12-21-05 Advanced RCC |
| Biomed 101 |
IL-2 side effect protectant |
Biomedics |
I |
| GVAX |
Vaccine |
Cell Genysis |
II |
| Celpene +IL-2 |
Histamine dihydrochloride |
Maxim |
II |
| CP461 |
Apoptotic antineoplastic |
Cell Pathways |
II |
| Dacogen ( decitabine) |
DNA methyltransferase inhibitor) |
MGI |
I |
| ELL-12 (ether lipid) |
Ether-based antineoplastic |
Elan |
II (RCC) |
| FK228 (depsipeptide) |
HDAC inhibitor |
Glouchester |
II |
| G250 (unconjugated cG250) |
Monoclonal antibody |
Wilex |
II (RCC) |
| GD0039 |
Immunomodulatory agent |
Inflazyme Pharmaceuticals |
II (RCC) |
| GTI-2040 |
Antisense |
Lorus Therapeutics |
II (RCC) |
| Irolfulven (MGI 114) |
Acylfulvene analog |
MGI |
I/II |
| MG98 |
Antisense |
MethylGene and MGI Pharma |
II (RCC) |
| MVA-MUC1-IL2 |
Gene therapy |
Transgene |
II |
| Neovastat |
Angiogenesis |
Aeterna Zentaris, Inc. |
III |
| Onconase (ranpirnase) |
Ribonuclease A homologue |
Alfacell |
II |
| Oncophage (HSPPC-96) |
Heat shock protein vaccine |
Antigenics |
III (RCC) |
| Patient Specific Vaccine |
Vaccine |
Genzyme |
I |
| Rencarex |
Monoclonal antibody |
Wilex AG |
III |
| |
|
|
|
| SB-485232 |
Recombinant IL-18 Immunomodulator |
GlaxoSmithKline |
II |
| |
|
|
|
| SU-11,248 (sutent) |
MKI -VEGFR, PDGFR, Kit, RET |
Pfizer Inc. |
Approved 1-26-06 Advanced RCC |
| Targretin capsule |
Retinoid |
Ligand Pharmaceuticals |
II |
| Taxoprexin (docosahexaenoic acid-paclitaxel) |
Taxane |
Protarga |
II |
| temsirolimus (CCI-779) |
mTOR inhibitor |
Wyeth |
III |
| WXG250 |
MoAb |
Wilex AG |
II |
|
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
 View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|
Patient Home
Meeting Calendar
